SHILPAMED

- Dispatch of letter to shareholders regarding the 39th Annual General Meeting (AGM) and Annual Report for FY 2025-26. - AGM to be held on Friday, September 11, 2026, at 11:00 AM (IST) via VC/OAVM. - E-voting cut-off date: September 04, 2026. - Remote e-voting: September 07, 2026 (09:00 AM) to September 10, 2026 (05:00 PM).

- Shilpa Medicare initiated a voluntary recall of 27,923 vials of Pemetrexed Injection (chemotherapy drug) in the US on July 29, 2026. - The recall was due to atypical discoloration not consistent with approved specifications and has been classified as a Class II recall by the US FDA. - The company states no adverse events have been reported and it does not foresee a material impact on its financials or operations.

- The Board of Shilpa Medicare Limited recommended a Final Dividend of Re. 0.60/- per equity share (Re. 1/- face value) for FY ended March 31, 2026. - The record date for dividend entitlement is September 4, 2026. - This communication details the deduction of Tax at Source (TDS) on the final dividend.

- Shilpa Medicare reported highest-ever quarterly revenue of ₹469 Cr (▲43% YoY) and EBITDA of ₹139 Cr (▲42% YoY) in Q1 FY27, achieving a 30% EBITDA margin. - Net Profit (PAT) increased 115% YoY to ₹101 Cr. - The company's financial health significantly improved, with net debt to EBITDA reducing to 1.3x from 6.7x and ROCE increasing to 12.5% (adjusted 18.3%). - The credit rating was upgraded from A+ to AA-. - Management anticipates robust growth, with steady growth for API and significantly higher growth for Biologics, driven by a strong pipeline and monetization of past investments. - Key product advancements include Aflibercept biosimilar launch in India in FY27, three near-term formulation filings (Abraxane, Enzalutamide, Abiraterone) targeted for FY28, and multiple NCE programs entering clinical studies and commercialization in FY27-FY28. - The company expects tax rates to normalize around 25% and EBITDA margins to remain stable at approximately 30% in the coming quarters.

- Audio recording of the Q1/FY2026-27 Conference Call held on August 5, 2026, has been uploaded to the company's website.

- Record Date for the final dividend for FY 2025-26 has been fixed as Friday, 4th September 2026. - The dividend is subject to shareholder approval at the Annual General Meeting (AGM) scheduled for 11th September 2026.

- Consolidated Revenue ₹46,578 Lakhs vs ₹32,147 Lakhs (▲44.9% YoY) - EBITDA ₹14,223 Lakhs vs ₹9,090 Lakhs (▲56.5% YoY) - PAT ₹10,088 Lakhs vs ₹4,688 Lakhs (▲115.2% YoY) - EBITDA Margin 30.5% vs 28.3% (▲226bps)

- Dr. Uday N. Harle has been appointed as the Chief Executive Officer (CEO) of Shilpa Biologicals Private Limited, a wholly-owned subsidiary of Shilpa Medicare Limited. - The appointment is effective from August 03, 2026. - Dr. Harle brings approximately 24 years of experience in the global biopharmaceutical industry.

- Concall Schedule for Q1-FY27 Earnings - Concall Date: Wednesday, August 05, 2026 - Concall Time: 16:00 hrs

- Shilpa Biologicals Private Limited, a material subsidiary of Shilpa Medicare Limited, received a credit rating from India Ratings and Research Pvt Ltd. - Bank loan facilities of INR 1,250 million were assigned a rating of 'IND A+/Stable/IND A1+'.

- Dr. Sridevi Khambhampaty has resigned as the Chief Executive Officer (CEO) of Shilpa Biologicals Private Limited, a material subsidiary of Shilpa Medicare Limited. - The resignation is effective from the closing hours of July 15, 2026, due to personal commitments.

- India Ratings and Research (Fitch Group) upgraded Shilpa Medicare Ltd's bank facilities to 'IND AA-/Stable/IND A1+' from 'IND A+/Positive/IND A1'. - Its subsidiary, Shilpa Pharma Lifesciences Ltd, also received upgrades for its bank facilities; one non-convertible debenture rating was withdrawn.

The provided PDF document is blank, and no content or financial data could be extracted for analysis.

- Shilpa Biologicals Pvt Ltd (a wholly-owned subsidiary of Shilpa Medicare) entered a co-development and supply agreement with Orion Corporation, Finland.- The agreement is for an intravenous (IV) Nivolumab biosimilar for the European market, targeting a ~USD4.1 billion market (2025 sales in Europe).- Shilpa Biologicals will lead product development and serve as the exclusive long-term commercial manufacturer and supplier.- Shilpa is entitled to receive development and regulatory milestone payments, in addition to supply revenue.

- Intimation of Closure of Trading Window for designated persons. - Effective from July 01, 2026, until 48 hours after declaration of un-audited Financial Results for the quarter ended June 30, 2026. - Board Meeting date for considering these results will be communicated in due course.

- Shilpa Biologicals Pvt. Ltd. (subsidiary) settled a legal dispute with Sartorius Stedim India Pvt. Ltd. for ₹9,00,00,000. - The original claim by Sartorius was for ₹20,13,47,308 plus interest. - The settlement was executed on June 23, 2026.

- Shilpa Biologicals Private Ltd, a material subsidiary of Shilpa Medicare Ltd, has commissioned a state-of-the-art Antibody-Drug Conjugate (ADC) GMP Manufacturing Facility. - The facility is fully operational, designed to meet global regulatory standards including US FDA and EMA, and is undergoing GMP qualification protocols. - This positions Shilpa as one of India's few companies offering fully integrated, end-to-end ADC Drug Substance development and manufacturing, leveraging its expertise in high potency compound manufacturing.

- Shilpa Medicare Limited declared the results of the postal ballot conducted from May 24, 2026, to June 22, 2026. - The Special Resolution for shifting the Company's Registered Office from one state to another and altering the Situation Clause of the Memorandum of Association was passed with 99.99% votes in favor.